ProQR Therapeutics N.V.
PRQR
$2.26
$0.052.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.90M | 20.36M | 20.43M | 19.38M | 16.64M |
| Total Other Revenue | 709.60K | 698.20K | 692.60K | 547.60K | 395.90K |
| Total Revenue | 18.61M | 21.06M | 21.13M | 19.93M | 17.04M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.61M | 21.06M | 21.13M | 19.93M | 17.04M |
| SG&A Expenses | 16.65M | 14.43M | 14.77M | 15.71M | 15.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.23M | 56.64M | 54.09M | 52.05M | 47.63M |
| Operating Income | -45.61M | -35.59M | -32.97M | -32.13M | -30.59M |
| Income Before Tax | -43.24M | -32.55M | -30.26M | -26.23M | -23.26M |
| Income Tax Expenses | 20.40K | -215.30K | -212.00K | -206.60K | -251.20K |
| Earnings from Continuing Operations | -43.26 | -32.34 | -30.04 | -26.03 | -23.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 0.00 | -315.60K |
| Net Income | -43.26M | -32.34M | -30.04M | -26.03M | -23.33M |
| EBIT | -45.61M | -35.59M | -32.97M | -32.13M | -30.59M |
| EBITDA | -43.14M | -33.11M | -30.46M | -29.67M | -28.19M |
| EPS Basic | -0.44 | -0.35 | -0.35 | -0.32 | -0.29 |
| Normalized Basic EPS | -0.28 | -0.22 | -0.22 | -0.23 | -0.22 |
| EPS Diluted | -0.45 | -0.35 | -0.35 | -0.32 | -0.29 |
| Normalized Diluted EPS | -0.28 | -0.22 | -0.22 | -0.23 | -0.22 |
| Average Basic Shares Outstanding | 391.75M | 368.07M | 344.35M | 326.14M | 325.45M |
| Average Diluted Shares Outstanding | 391.75M | 368.07M | 344.35M | 326.14M | 325.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |